6'-N-[N^α-[(guanin-9-yl)acetyl]-N^ε-(benzyloxycarbonyl)-D-lysyl]neamine | 886208-90-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6'-N-[N^α-[(guanin-9-yl)acetyl]-N^ε-(benzyloxycarbonyl)-D-lysyl]neamine
• CAS: 886208-90-8
• 化学式: C₃₃H₄₉N₁₁O₁₁
• 分子量: 775.819
• InChiKey: CWPKDBPTJSRIKN-BCXBCHDDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.66
• 重原子数：
  55.0
• 可旋转键数：
  15.0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  363.56
• 氢给体数：
  12.0
• 氢受体数：
  18.0

反应信息

• 作为反应物：
  描述：

  6'-N-[N^α-[(guanin-9-yl)acetyl]-N^ε-(benzyloxycarbonyl)-D-lysyl]neamine 以100%的产率得到6'-N-[N^α-[(guanin-9-yl)acetyl]-D-lysyl]neamine
  参考文献：
  名称：

  Neamine derivatives having a nucleobase with a lysine or an arginine as a linker, their synthesis and evaluation as potential inhibitors for HIV TAR–Tat

  摘要：

  Neamine derivatives hearing a nucleobase, adenine, cytosine. guanine or thymine with a lysine or an arginine as a linker have been synthesized and its potential as the inhibitor for HIV TAR-Tat interaction examined. Among them, modified neamine having an arginine-nucleobase showed a higher inhibition than that of the one having a lysine-nuclcobase. The difference of the nucleobase anchor did not characterize inhibition specificity. Also, stereochemistry of the amino acid in the compounds causes no difference in the inhibition for TAR-Tat. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.11.056
• 作为产物：
  描述：

  tert-butyl Nα-[(guanin-9-yl)acetyl]-Nε-(benzyloxycarbonyl)-L-lysinate 在 WSC*HCl 、 溶剂黄146 、 三氟乙酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 30.0h， 生成 6'-N-[N^α-[(guanin-9-yl)acetyl]-N^ε-(benzyloxycarbonyl)-D-lysyl]neamine
  参考文献：
  名称：

  Neamine derivatives having a nucleobase with a lysine or an arginine as a linker, their synthesis and evaluation as potential inhibitors for HIV TAR–Tat

  摘要：

  Neamine derivatives hearing a nucleobase, adenine, cytosine. guanine or thymine with a lysine or an arginine as a linker have been synthesized and its potential as the inhibitor for HIV TAR-Tat interaction examined. Among them, modified neamine having an arginine-nucleobase showed a higher inhibition than that of the one having a lysine-nuclcobase. The difference of the nucleobase anchor did not characterize inhibition specificity. Also, stereochemistry of the amino acid in the compounds causes no difference in the inhibition for TAR-Tat. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.11.056